BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing CODIT™ (characterized oral desensitization immunotherapy) treatments for life-threatening food allergies, today announced the appointment of Douglas Sheehy as General Counsel and Secretary. Mr. Sheehy has more than 20 years of both in-house and law firm experience, including nearly a decade as general counsel.
“As Aimmune experiences rapid growth, we’re committed to continuing to operate with the highest integrity and to upholding the best practices of corporate governance and compliance across all of our functions — clinical development, research, regulatory, and financial and commercial operations. Doug has proven sound judgment in meeting critical business objectives, and he will be a key contributor as we move forward,” said Aimmune CEO Stephen Dilly, M.B.B.S., Ph.D.
Mr. Sheehy joins Aimmune from Codexis, Inc., a developer of biocatalysts for the pharmaceutical and fine chemical industries, where he was hired as General Counsel and Secretary in 2007. Most recently, he was also the company’s Chief Administrative Officer. Previously, Mr. Sheehy spent five years in key legal roles at CV Therapeutics, Inc., a publicly held biopharmaceutical company that was subsequently acquired by Gilead in 2009. He began his legal career as a corporate attorney at Gunderson Dettmer LLP. Mr. Sheehy holds a B.A. in history from Dartmouth College and a J.D. from American University, where he served as Editor-in-Chief of the Law Review.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s CODIT™ (characterized oral desensitization immunotherapy) system uses rigorously characterized product candidates with gradual, controlled up-dosing protocols to obtain clinically meaningful desensitization to food allergens. Aimmune’s first CODIT product, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age. Aimmune’s Phase 3 trial of AR101, PALISADE, is now enrolling patients. For more information, please see www.aimmune.com.